MacroGenics, Inc.
MGNX
Positions held
Your positionsMGNX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $226.14M | Enterprise value | $87.92M | Trailing P/E | — | Forward P/E | -2.42 |
| PEG | — | Price / book | 5.27 | Beta | 1.21 | Dividend yield | 0.00% |
| Revenue growth | 3.8% | Earnings growth | — | Gross margin | -0.7% | Operating margin | -42.2% |
| Profit margin | -8.3% | ROE | -2.3% | ROA | -8.1% | Debt / equity | 0.82 |
| Current ratio | 2.96 | Free cash flow | -$69.41M | Analyst recommendation | buy | Mean target | $8.00 |
| 52w high | $5.08 | 52w low | $1.29 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $32.8M | $20.8M | $41.2M | $72.8M | $6.9M | — |
| Op margin | -42.2% | -161.0% | -29.3% | 25.6% | -629.3% | — |
| Net income | $19.5M | -$36.8M | -$14.2M | $16.8M | -$36.3M | — |
| Gross margin | — | 54.1% | 75.5% | 84.1% | 194.1% | — |
| Gross profit | — | $11.2M | $31.1M | $61.3M | $13.3M | $7.8M |
| Operating income | -$13.9M | -$33.4M | -$12.1M | $18.6M | -$43.2M | — |
- Revenue +58% vs prior quarter ($33M vs $21M).
- Gross margin 54.1% (was 75.5% prior quarter).
- Operating margin expanded to -42.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $150M | $150M | $58.7M | $150M | — |
| Op margin | -48.7% | -73.7% | -286.4% | -80.9% | — |
| Net income | -$74.6M | -$67.0M | -$9.1M | -$120M | — |
| Gross margin | 75.9% | 91.8% | 86.0% | 95.1% | — |
| Gross profit | $113M | $138M | $50.5M | $143M | — |
| Operating income | -$72.8M | -$111M | -$168M | -$121M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-23 · Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-09-09 · MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-20 · Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
2026-08-17 · B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating
2026-08-15 · Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
2026-08-13 · MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 · MacroGenics: Q2 Earnings Snapshot
2026-08-06 · Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates
2026-07-23 · MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Price (daily)
Full chart · RSI · MACD · patterns